Valuation: Collegium Pharmaceutical, Inc.

Market Cap 1.15B 1.02B 943M 867M 1.63B 112B 1.66B 11.28B 4.4B 54.52B 4.33B 4.24B 189B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.15B 1.02B 943M 867M 1.63B 112B 1.66B 11.28B 4.4B 54.52B 4.33B 4.24B 189B EV / Sales 2026 *
1.33x
EV / Sales 2027 * 1.34x
Free-Float
77.32%
Yield 2026 *
-
Yield 2027 * -
1 day+2.51%
1 week-1.87%
Current month-1.69%
1 month+2.80%
3 months+10.25%
6 months-21.78%
Current year-23.13%
1 week 34
Extreme 34
36.92
1 month 34
Extreme 34
38.5
Current year 30.13
Extreme 30.13
49.31
1 year 29.19
Extreme 29.19
50.79
3 years 20.95
Extreme 20.95
50.79
5 years 14.04
Extreme 14.04
50.79
10 years 7.37
Extreme 7.37
50.79
Manager TitleAgeSince
Chief Executive Officer 51 12/11/2024
Director of Finance/CFO 50 24/05/2021
Chief Tech/Sci/R&D Officer - 01/10/2021
Director TitleAgeSince
Director/Board Member 78 01/01/2015
Chairman 69 15/05/2025
Director/Board Member 72 01/02/2014
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Fiscal year

Chairman

17,400 0.0536%
18/5/26 Sell

Director

-20 0.0001%
15/5/26 Fiscal year

Director

21,527 0.0664%
Change 5-day change 1-year change 3-year change Capi.($)
+2.51%-1.87%+9.81%+57.41% 1.13B
+1.97%+1.43%+48.44%+156.66% 1,037B
+1.42%+3.72%+53.32%+52.34% 615B
+1.43%+0.99%+34.83%+78.74% 448B
+5.14%+5.40%+33.75%+27.28% 326B
+1.85%+3.57%+37.09%+39.87% 293B
-0.11%+0.48%+18.87%+17.81% 264B
+0.25%-4.62%-27.66%-42.25% 216B
+1.49%-0.02%+20.14%+58.21% 198B
+0.40%-3.99%+15.23%+62.28% 162B
Average +1.63%-0.28%+24.38%+50.83% 355.86B
Weighted average by Cap. +1.73%+1.12%+35.40%+75.23%

Financials

2026 *2027 *
Net sales 870M 765M 711M 654M 1.23B 84.24B 1.25B 8.5B 3.31B 41.09B 3.27B 3.19B 143B 860M 757M 703M 646M 1.21B 83.3B 1.23B 8.4B 3.28B 40.63B 3.23B 3.16B 141B
Net income - -
Net Debt - -
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
423
Date Price Change Volume
23/07/26 US$35.59 +2.51% 253,217
22/07/26 US$34.72 -3.15% 231,337
21/07/26 US$35.85 +0.87% 301,579
20/07/26 US$35.54 -1.50% 383,546
17/07/26 US$36.08 -0.52% 316,576
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
35.59USD
Average target price
53.60USD
Spread / Average Target
+50.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COLL Stock